Radiopharm Theranostics Advances RAD101 Phase 3 Trial Planning with FDA Meeting Set
Radiopharm Theranostics is gearing up for a pivotal Phase 3 trial of its brain metastases imaging agent RAD101, following strong Phase 2b results and an upcoming FDA meeting to finalise trial design.
- Scheduled FDA End-of-Phase 2 meeting on October 1, 2026
- RAD101 Phase 2b trial achieved 93% concordance with MRI
- FDA Fast Track Designation secured for RAD101
- Partnership with Siemens Healthineers for manufacturing and distribution
- Targeting recurrent brain metastases diagnosis in solid tumor patients
FDA Meeting to Define Phase 3 Trial Blueprint
Radiopharm Theranostics (ASX:RAD) has set a crucial milestone with an End-of-Phase 2 meeting scheduled for October 1, 2026, with the U.S. Food and Drug Administration. The agenda: to align on the pivotal Phase 3 trial design for RAD101, its novel imaging agent aimed at diagnosing suspected recurrent brain metastases after radiotherapy. This meeting will determine key trial parameters such as patient enrolment numbers and primary and secondary endpoints, shaping the regulatory pathway ahead.
Strong Phase 2b Data Underpinning Regulatory Confidence
RAD101’s Phase 2b trial delivered a noteworthy 93% concordance rate with MRI across evaluable lesions, surpassing the primary endpoint and reinforcing its diagnostic potential. The imaging agent targets fatty acid synthase (FASN), a protein overexpressed in brain metastases from various solid tumors, enabling selective tumour uptake visible on PET scans. This metabolic imaging showed promise in clarifying ambiguous MRI results, potentially addressing a critical gap in the surveillance of intracranial metastatic disease (IMD).
With over 300,000 U.S. patients diagnosed annually with cerebral metastases, improved diagnostic tools like RAD101 could significantly impact patient management. The agent’s FDA Fast Track Designation further underscores the agency's recognition of its potential to distinguish recurrent disease from treatment effects, a persistent challenge in neuro-oncology.
Strategic Manufacturing Partnership to Support Trial Execution
To facilitate the upcoming Phase 3 trial, Radiopharm has partnered with Siemens Healthineers, which will manufacture and distribute doses of 18F-labeled RAD101 in the U.S. This collaboration is critical to ensuring supply chain robustness and trial logistics ahead of the registrational study. Siemens’ involvement also signals confidence in RAD101’s commercial viability should the trial succeed.
Positioning RAD101 in a Growing Clinical Need
Intracranial metastatic disease incidence is rising, partly due to improved systemic therapies extending primary tumour control but leaving patients vulnerable to brain metastases. Current imaging standards, primarily contrast-enhanced MRI, have limitations in follow-up surveillance, often leading to equivocal findings. RAD101’s ability to provide metabolic imaging of FASN activity offers a promising complementary approach, potentially enabling more accurate detection and better-informed treatment decisions.
Radiopharm aims to be Phase 3 ready by the end of 2026, with the FDA meeting expected to clarify the final trial design. This progress builds on the company’s broader oncology radiopharmaceutical pipeline and recent capital raising efforts to fund clinical development, positioning RAD101 as a potential game-changer in brain metastases diagnosis.
Bottom Line?
The October FDA meeting will be pivotal in shaping RAD101’s Phase 3 trial, with potential to unlock a new diagnostic standard for recurrent brain metastases.
Questions in the middle?
- Will the FDA endorse the proposed patient enrolment and endpoints for RAD101’s Phase 3 trial?
- How quickly can Radiopharm transition from Phase 2b success to Phase 3 initiation and enrolment?
- What impact will the Siemens Healthineers partnership have on RAD101’s commercial scalability post-approval?
